AquaBounty Technologies is conducting research and development of the commercial viability of a group of proteins commonly known as antifreeze proteins. Co. has the licensing rights for a gene construct (transgene) used to create a breed of farm-raised Atlantic salmon. Co. has obtained regulatory approval from the U.S. Food and Drug Administration for the production and sale of its genetically engineered AquAdvantage salmon product (GE Atlantic salmon) in the U.S.; from Health Canada for the production and sale of its GE Atlantic salmon product in Canada; and from National Biosafety Technical Commission for the sale of its GE Atlantic salmon product in Brazil. The AQB stock yearly return is shown above.
The yearly return on the AQB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AQB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|